Ipsen Establishes Optimal Biological Dose For BN83495 Steroid Sulphatase Inhibitor

Ipsen reports the preliminary results of a Phase I trial in metastatic breast cancer with BN83495, first-in-class orally available irreversible steroid sulfatase (STS) inhibitor. In the course of the study, the optimal biological dose was determined as 40mg once daily oral administration for future phase II trials in this indication.

The compound is currently in further clinical development for advanced endometrial cancer (Phase II) as well as in Phase I clinical evaluation for castrate resistant prostate cancer in North America.

Stephane Thiroloix, executive vice-president of corporate development at Ipsen, said: “Following this important clinical milestone, we look forward to progressing the global development of BN83495 in this indication and in other selected hormone-dependent cancer indications.”

In the study 35 post-menopausal women with estrogen receptor (ER) positive metastatic breast cancer, having already received one or two different types of hormonal therapy for their disease, were treated with increasing doses of BN83495 given orally once daily.